As we age, we all lose sensitivity to insulin and begin, gradually or rapidly, to poison our bodies with excess sugar in the blood. This happens to almost everyone, and it is only when the symptom is particularly severe that it is diagnosed as (type 2) diabetes. Metformin is a drug that has been used to treat diabetes for 50 years, but it is only recently that epidemiologists have begun to notice that patients on metformin have lower rates of cancer and heart disease. Of course, cancer and heart disease were elevated to begin with in diabetics. But the question has been asked: will metformin provide a benefit for “normal” aging, and lower cancer risk for people who are not diagnosed with diabetes? Vladimir Anisimov from University of Glasgow that it’s time to test metformin for its anti-cancer and life extension potential for non-diabetics. He is a biostatistician, an epidemiologist and not a physiologist. But a good part of the reason to think that this might work comes from theory.Metformin and Caloric Restriction The only intervention that is known to consistently extend life span across many different species is caloric restriction. Animals seem to be widely adapted to stabilize their populations by suppressing death from aging under conditions of starvation (and raising the internally-programmed death rate when there is plenty of food). How does the individual metabolism detect when it is starving? The signal comes mainly from the insulin metabolism. The body responds to chronically elevated insulin by decreasing sensitivity to insulin, and raising insulin levels yet further in a positive feedback loop that cascades toward death. Metformin interrupts this cycle in a manner similar to lowered food intake. Since most people don’t tolerate chronic hunger very well, a drug that offers the benefits of a lean diet without having to cut calories would be highly prized. Such a drug is called a caloric restriction mimetic, and there is some reason to believe that iswhat metformin does. (Many people taking metformin experience actual weight loss as well.) The health benefits of metformin for diabetics are striking, and are not shared by other drugs that treat only the diabetes. Metformin . But cancer is already elevated in diabetics. If the reduction in cancer had been to values below the rates in non-diabetics, then metformin for non-diabetics would seem to be a slam dunk. But in reality this sizable benefit brings cancer rates down , but not further. So the benefits for non-diabetics remain speculative. Life extension in rats and mice Over the years, there have been many studies of metformin’s effects on mice and rats. Most show some life extension, and the best result increased life span by 38%. Metformin seems to work better for mice than rats, and better for females than males. Here is a table () summarizing results in rodents. Strain Sex Treatment No. of animals Life span, days References Mean Last 10% of survivors Maximum Mouse C3H/SnFemale Control 30 450 ± 23.4 631 ± 11.4 643 [] Phenformin 24 545 ± 39.2 (+21.1%) 810 ± 0 * (+28.4%) 810 (+26%) FVB/N Female Control 34 264 ± 3.5 297 ± 7.3 311 [] Metformin 32 285 ± 5.2 (+8.0%) 336 ± 2.7 (+13.1%)* 340 (+16.2%) FVB/N Female Control 15 285 ± 12 396 ± 0 396 [] Metformin 20 304 ± 10 352 ± 7 359 SHR Female Control 50 388 ± 29.2 727 ± 22.5 814 [] Metformin 50 535 ± 31.9* (+37.9%) 878 ± 6.6* (+20.8%) 898 (+10.3%) NMRI Female Control 50 346 ± 11.9 480 ± 9.2 511 [] Diabenol 50 369 ± 12.9 504 ± 6.4* (+5.9%) 518 129/Sv Male Control 41 662 ± 27.7 951 ± 32.3 1029 [] Metformin 46 573 ± 26.5 (-13.4%)* 931 ± 30.4 1044 129/Sv Female Control 47 706 ± 20.8 910 ± 8.9 930 Metformin 48 742 ± 16.3 (+5.1%) 913 ± 19.2 966 (+3.9%) Rat LIO Female Control 41 652 ± 27.3 885 ± 11.3 919 [] Phenformin 44 652 ± 28.7 974 ± 16.2** (+10.1%) 1009 (+9.8%) Female Control 74 687 ± 19.2 925 ± 22.5 1054 [] Buformin 42 737 ± 26.4 (+7.3%) 1036± 38.9* (+12%) 1112 (+5.5%) Fischer-344 Male Control 31 796 ± 170 1039± 29.6 1065 [] Metformin 40 815 ± 186 1061 ± 2.5 1062 The difference with control is significant: * – p < 0.05 ; ** p < 0.01 (Student’s test) (Phenformin and buformin are chemical sisters of metformin. Metformin is prescribed for people because it has the lowest rate of complications and side effects.) Mechanism for protection against cancer There is also “test tube” evidence for metformin’s effect on cancer: Cancer cells are supposed to detect that they are diseased and eliminate themselves harmlessly and promptly via a mechanism called apoptosis. Cancer can’t become cancer until this mechanism is suppressed, mutated away so that the cancer cells don’t automatically commit suicide. In lab studies of cell cultures, cancer cells respond to metformin by restoring the apoptosis mechanism that was suppressed when they became cancerous in the first place. Metformin shrinks tumors by inducing cancer cells to commit suicide. On this basis, metformin is as a treatment for cancer patients,with first application to breast cancer. Side-effects Complications and risks from metformin are unusual, but they do exist. The main one is called – a rare but serious disease that is almost unknown outside metformin patients. A conscientious doctor who prescribes metformin will counsel the patient to be alert to the symptoms. Research study would be most beneficial – but who will pay the bill? For those who are overweight in middle age or pre-diabetic, there is much to recommend metformin. But are there benefits for middle-aged people who are not in this category? The only way to know for sure is through double-blind clinical trials with at least several thousands of patients. But who will fund such a study? Metformin is a cheap, generic prescription, decades out of patent. There is no company with the motivation to invest in it. Even if such a study is begun, it will require ten years at best before we know anything. In the meantime, a few and asking their doctors for aprescription, or even self-medicating through on-line pharmacies. Perhaps we will learn from their experience. For basic information about healthy living for a long life, see the author’s permanent page at .
